Pharming Group (NASDAQ:PHAR) Short Interest Up 350.0% in September

Pharming Group (NASDAQ:PHAR) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 900 shares, an increase of 350.0% from the September 15th total of 200 shares. Based on an average trading volume of 900 shares, the short-interest ratio is currently 1.0 days.

Separately, Zacks Investment Research lowered Pharming Group from a “hold” rating to a “sell” rating in a research report on Thursday, August 19th.

NASDAQ PHAR opened at $9.02 on Thursday. The firm has a market cap of $582.80 million and a PE ratio of 15.55. The company has a debt-to-equity ratio of 0.73, a current ratio of 5.25 and a quick ratio of 4.74. The stock’s 50 day simple moving average is $10.10 and its 200 day simple moving average is $11.44. Pharming Group has a one year low of $9.02 and a one year high of $21.99.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings data on Thursday, August 5th. The company reported $0.06 EPS for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.05. The firm had revenue of $49.60 million during the quarter, compared to the consensus estimate of $64.13 million. As a group, equities analysts expect that Pharming Group will post 0.02 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. UBS Group AG boosted its position in Pharming Group by 173.8% in the 1st quarter. UBS Group AG now owns 2,508 shares of the company’s stock valued at $32,000 after buying an additional 1,592 shares during the last quarter. Morgan Stanley boosted its position in Pharming Group by 5,208.3% in the 2nd quarter. Morgan Stanley now owns 2,548 shares of the company’s stock valued at $29,000 after buying an additional 2,500 shares during the last quarter. Finally, Cowen Prime Advisors LLC bought a new position in shares of Pharming Group in the 2nd quarter worth $71,000. Hedge funds and other institutional investors own 0.31% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.

Further Reading: Moving Average (MA)

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with's FREE daily email newsletter.